Next-generation sequencing (NGS) technology is capable of sequencing millions or billions of DNA molecules simultaneously. Therefore, it represents a promising tool for the analysis of molecular targets for the initial diagnosis of disease, monitoring of disease progression, and identifying the mechanism of drug resistance. On behalf of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology (CSCO) and the China Actionable Genome Consortium (CAGC), the present expert group hereby proposes advisory guidelines on clinical applications of NGS technology for the analysis of cancer driver genes for precision cancer therapy. This group comprises an assembly of laboratory cancer geneticists, clinical oncologists, bioinformaticians, pathologists, and other professionals. After multiple rounds of discussions and revisions, the expert group has reached a preliminary consensus on the need of NGS in clinical diagnosis, its regulation, and compliance standards in clinical sample collection. Moreover, it has prepared NGS criteria, the sequencing standard operation procedure (SOP), data analysis, report, and NGS platform certification and validation.
Introduction
Precision medicine, also referred to as personalized medicine, is an emerging concept in healthcare that adapts therapy based on the genome, physiology, and lifestyle of the patient. This method of disease management requires the incorporation of clinical and genetic data, enabling the clinicians to provide an efficient treatment course to attain a significant outcome 1, 2 . In the present era of personalized oncology therapy, a comprehensive analysis of cancer driver genes and their mutations underlying the pathophysiology of cancer development is crucial for designing the most appropriate treatment strategy for patients using targeted therapies 3 . Although Sanger sequencing 4 is still being used as a gold standard in clinical applications, the more recently developed second-generation technology, namely the nextgeneration sequencing (NGS) technology, has superseded it owing to simpler usage and functional advantage [5] [6] [7] .
Over the last decade, economic growth and changing lifestyle in China has led to an increase in the incidence of cancer and cancer-related mortality 8 . Continuous progressive research is being conducted in the areas of molecular targeted therapy, which is currently considered as a promising treatment. China has supported research initiatives directed towards progress in precision medicine, considering it as a new phase in health care. On September 17 th , 2015, the Chinese Society of Clinical Oncology (CSCO) convened a group of renowned oncologists, pathologists, biologists, and NGS experts in Xiamen to set up the China Actionable Genome Consortium (CAGC). The CAGC announced the start of the precision oncology initiative (CAGC-POI), and the framework and goals of this organization were laid out. According to the 2015 Chinese cancer report, the most commonly diagnosed cancers in China are carcinomas of the lung and bronchus, stomach, esophagus, liver, colorectum, and breast in the order listed. The overall national incidence of all cancer types in 2015 was approximately 4.29 million, and cancer-related mortality was 2.81 million people 8 . Therefore, there is a significant medical need for precision oncology for diagnosis and treatment in China.
Under the preliminary consensus on the clinical application of NGS, the CAGC-POI project stage I aims to utilize NGS technology to profile cancer driver genes for five malignant solid tumors, including lung cancer, breast cancer, hepatocellular carcinoma, gastric cancer, and colorectal cancer. On September 27th 2015, hematopoietic malignancy was included as the 6th tumor type after discussions between CSCO Chairman Professor Yi-long Wu, Academician Zhu Chen (President of Chinese Medical Association), and Academician Saijuan Chen, aiming to perform a more comprehensive mutational atlas study on leukemia. Under the consensus, the CAGC-POI will determine a set of optimized standard operating procedures (SOPs) and mutational atlases of driver gene mutations across these six cancers. This will guide the recruitment of patients with such mutations into precision medicine-related clinical trials. In the final version of the consensus, standards and compliance rules suitable for clinical oncology in China regarding NGS techniques, analysis tools, along with diagnosis and treatment models will be put forward, which will further fill the gap between NGS laboratory and clinical application, ultimately improving the health of cancer patients. The goal of CAGC-POI stage I is to establish a consensus on the application of NGS technology in clinical oncology, based on the advice and opinions from the expert group, which would serve as a guideline for oncology-related clinical and personal testing in the near future. Currently, there is an urgent need for a consensus based on the discussions from expert professionals in all related fields to guide the application of NGS in cancer diagnosis and precision medicine.
Overview of NGS technology
NGS technology, also referred to as massively parallel sequencing (MPS), is a parallel sequencing technology applied to specific samples obtained from patients with cancer, which has the ability to sequence billions of DNA base pairs in a single run.
NGS for cancer samples can range from targeted gene panels analyzing few thousand base cells to whole-exome sequencing (WES) and whole-genome sequencing (WGS) analyzing 40 to 50 million bases and 3.3 billion bases, respectively. The target panels in NGS offer a larger exon coverage, greater than that with WES and WGS applications. The targeted panel sequencing detects only the specific carcinogenic genes, while WES and WGS can identify unknown variants along with known mutations. WGS provides the most unbiased examination of the cancer genome, thereby paving the way for the discovery of previously unrecognizable mutations 9 .
Presently, NGS of targeted gene panels are very common in clinical practice for the purpose of finding targetable genomic alterations. Whole exome or genome sequencing are mainly used for research purposes. NGS of gene panels longer than one million megabases are under extensive validation for TMB (tumor mutational burden) estimation, aiming to serve as surrogate test for whole exome sequencing based TMB analysis. In the future, whole exome sequencing might be validated for the use of identifying functional neoantigens or other clinical biomarkers.
Although NGS technology has the advantage of a highthroughput workflow and can discover hereto unknown mutations 10, 11 , it also confronts many challenges such as technology, data management, data analysis, interpretation, reporting, and genetic consulting. Many publications and international consensus have reported the application of NGS in single-gene inheritance diseases and prenatal diagnostics [12] [13] [14] [15] ; however, there has been no consensus on the application of NGS technology in clinical oncological practice, especially when used in cancer precision diagnosis and treatment to date 16 . With the widespread scope of tumor gene testing, NGS for precision diagnostics has gradually progressed from single-gene analysis to the profiling of several hundreds of genes. It is possible in the future that integrated information from the exome, transcriptome, whole genome, and epigenome will be adopted into clinical practice. Furthermore, as biotechnology is also evolving, it is foreseeable that the application of high-throughput NGS in clinical diagnosis and precision treatment will change perpetually in terms of testing technology, analysis tools, variant interpretation, etc., in the future, which will also bring various challenges to the practical application.
This technical consensus describes quality requirements, clinical tumor-related NGS testing content, sample processing, sequencing procedures, data management, informatics analysis, interpretation of reports, and consulting. This consensus also describes patient-informed consent and quality control of NGS tests, and adds a note on the differences in research and diagnostic NGS.
Quality requirements of NGS in cancer diagnosis
With evolving technology, it is of crucial importance to understand the current status of NGS technology in order to ensure a superior survival outcome and guarantee the wellbeing of the patient. A variety of NGS platforms are being used in different clinical laboratories. All laboratories, regardless of the platform used, should conduct NGS tests in accordance with the recommendations in this consensus and use them to validate the platform and associated analytical tools for clinical use.
Quality management (QM) plays a pivotal role in the standardization of NGS workflow by providing basic guidelines to ensure an advanced reproducibility of data and high turnover with reduced cost. Quality documentation containing procedural instructions and verified documents is the preliminary requirement to a good standardization method 17 , which improves the transparency and reliability of the results. One of the most important criteria for QM is quality assurance (QA). The QA program provides quality control (QC) methods for the predetermined checkpoints, such as contamination identification including initial sample check, fragmentation, library evaluation, error rate monitoring, and data analysis. These methods assist to confirm the formerly established performance status of a sample and indicate an error in case of any change in the status. The aforementioned QC features ensure that no sequence or sample data is used in the testing without meeting the established laboratory quality standards, and the QA procedure minimizes the risk of errors due to contamination. This is of central importance, especially in the case of a high or unlikely false-positive rate in assays or in detection of unknown agents 18, 19 . Many professional organizations have recommended the use of reference standards to minimize errors of inappropriate analysis leading to misdiagnosis by reducing bias associated with any method [18] [19] [20] [21] [22] [23] [24] [25] . These reference standards reflect a wide range of genomic features assessed by the NGS assay, advancing precision and reducing the systematic sequencing errors 26 .
In case of multigene detection of tumors, a specific NGS test needs to be designed to clearly describe the gene status required for clinical diagnosis and treatment. NGS tests should be fully validated in terms of analysis and technological capabilities, before being used in clinical practice. Several factors affect the quality of NGS results: platform, target region enrichment, library preparation, amplification efficiency, sequencing data volume, bioinformatics analysis pipeline, etc. NGS testing results for specific mutation sites that have low data quality should be validated by other methods before clinical application. Experts performing the testing in laboratories and consultants should have adequate communication channels and informed consent from patients regarding the advantages and disadvantages of conducting a tumor NGS test. Simultaneously, clinicians should understand the medical implications of specific NGS tests.
Recommendations
(1) Standardization of NGS assay with complete validation is necessary for its application in clinical practice for diagnosis of cancer driver gene mutations, in order to meet the clinical diagnostic standards. (2) Laboratories should determine the content of the assay with relevant technical parameters and also specify the purpose and utility of the NGS testing. (3) When used as a reference for deciding on targeted therapy, the NGS test results should identify the variations in genes that can be targeted for a particular drug. When used for molecular classification, an analytical model needs to be validated before further application to predict superior efficacy and prognosis of NGS testing.
NGS test content in clinical oncology
In routine clinical practice, along with the differential diagnosis suggested by the physician, a genetic test is recommended so as to obtain a confirmatory diagnosis with the laboratory reporting the wide range of genes analyzed, test methods used, and the performance parameters of every test. Therefore, for higher sensitivity and specificity, the initial testing is done with disease-targeted panels based on the relevant gene regions related to the disease. The referring physicians are recommended to provide detailed phenotypic data, such that the data can aid the laboratory in interpreting the results. In oncology, since a wide range of genomic variants exist within a single tumor type, or similar driver gene mutations are found among different kinds of tumors, the therapeutic strategies could be different for a single tumor, or a similar treatment could be applied to different tumor types 27, 28 . Thus, molecular classification of tumors based on specific genomic characteristics may move beyond traditional histopathological categorization and become the key step in cancer diagnosis and treatment 29 . Owing to this genomic phenomenon, elaborate disease panel testing is recommended to track the disease phenotype and correlate it with the genotype. Only those genes with clear scientific evidence of clinical relevance should be included in the disease-targeted gene panel. In case of overlapping phenotype, laboratories should consult with the physicians to restrict the analysis to a subpanel related to sub-phenotype to reduce the number of less relevant variants. Further, during exome and genome sequencing, the laboratories should be aware of the commercially available reagents and refractory areas in the experiment design 19 .
In recent years, multi-genotyping of tumors has shown to have a significant impact on drug development strategies with two new designs of targeted-therapy clinical trials: umbrella trials and basket trials. The former involves the same histological cancer with different driver gene mutations that could be potentially treated with different targeted drugs; the latter involves the same genomic mutation found in different histological tumors that could potentially be treated with a single targeted drug 30, 31 . In both clinical practices and clinical trials, the content of an NGS test for genotyping requires meticulous design and verification of technical reliability. This content, including candidate genes, targeted testing regions, and actionable variants should be well defined within the NGS test.
The establishment and development of the "core gene list" should be patient-oriented, fully integrated with the precision medicine concept from clinical oncologists, and combined with proper application and operability. In lung cancer, the current National Comprehensive Cancer Network (NCCN), Domestic Lung Cancer Clinical Guidelines and National Health and Family Planning Commission Diagnosis and Treatment Norms suggest that some driver gene variants including EGFR mutations, KRAS mutations, ALK rearrangements (fusion), ROS1 rearrangements (fusion), variable shear variations in MET exon 14, MET copy number amplification, RET rearrangements (fusion), HER2 mutations or amplification, and BRAF mutations are the essential parts of the "core gene list" 32 . The other core genes include HER2, BRCA1, BRCA2, ESR1, and other genes in breast cancer 33 From the perspective of clinical oncology in the CAGC-POI project, test content (the gene panel and its genomic region) should not only include tumor-specific gene panels, but also a large and comprehensive gene panel. Moreover, because gene mutation profiles of solid tumors and hematologic malignancies are significantly different, comprehensive gene panels for these two different malignancies should be designed separately. "Actionable genes" refer to driver genes and associated upstream and downstream regulators to which the therapeutic drug may be implemented in order to inhibit tumor progression or regress the tumor. In addition, actionable gene variations can also be used to determine molecular subtypes in diagnosis or prognosis. The first category of "actionable gene" is referred to as Level 1 actionable alterations, which includes clinical genomic variants published in various international and domestic guidelines (CSCO, ASCO, NCCN, ESMO, etc.), printed in the drug labels, related to indications approved by the food and drug administration of the USA (FDA)/China Food and Drug Administration CFDA, and having definite molecular diagnostic or prognostic value. The second category, described as Level 2 actionable alterations, includes drug-related targets in ongoing phase 1-3 clinical trials, mutations as inclusion criteria in current or upcoming clinical trials, drug targets of other tumors or indications in international and domestic guidelines, and targets for adjuvant diagnosis or prognosis. In the NGS test, direct analysis of tumor specimens without leukocyte DNA control is accepted for Level 1, while matched leukocyte DNA control is strongly recommended for larger gene sets for Level 2 actionable alterations, or for large groups of targets ranging from hundreds of genes to the whole exome.
Recommendations
(4) Application of a core panel list with a clear distinction of genes that need to be included in clinical molecular diagnostics, which is formed after a joint discussion by multidisciplinary experts including clinical oncologists from specific subspecialties and laboratory technologists. (5) Further, "actionable gene" variations may affect clinical decisions and thus guide the clinicians in the diagnosis and treatment regimen planning based on genotyping of test results. As continuous studies are performed on the mechanism of tumorigenesis, it is necessary to discuss and update the gene list regularly based on the progress of important clinical research. Comprehensive NGS tests on more genes will certainly provide more valuable clinical information. (6) Due to the redundancy and complexity of the tumor signaling pathway, annotations depicting genomic alterations and potential actionable sites, or signaling pathways, should be clearly described for each gene. In practice, the increase in the number of tested genes should not be at the expense of the quality of core genes.
Verification of technical parameters is vital to ensure the accuracy of NGS testing results
All NGS measurement parameters should be explicitly stated.
The batch and relevant characteristics of analysis specimens to be assayed should be recorded. Testing laboratories have the responsibility of maintaining a structured database to ensure the integrity of the testing platform, branch projects, and sample processing. Each sample should receive a unique identifier during the testing and analysis. During the verification of platform stability, all instruments and reagents should meet quality standards to ensure high accuracy and precision in the investigation of specific driver genes.
The following relevant parameters related to the technical verification process should be recorded: (i) sample-related patient information, unique identifiers, time and date of reception, storage, and processing; (ii) name, manufacturer, and batch number of reagents used in DNA/RNA processing and quality indicators (such as RIN, etc.); (iii) data analysisand database management-related software (version number, analysis parameters), data-related parameters (data size, QC, etc.), database security, and backup status 18, 23, [38] [39] [40] [41] [42] [43] .
Recommendations
(7) The NGS testing process and bioinformatics analysis pipeline should be fully optimized for specific platforms and tests, with pipeline validation providing parameters for their analytical sensitivity and specificity. (8) Analytical sensitivities and specificities should be established for each type of variant during pipeline validation. This is due to the differences in analytical methods among variation types including single-nucleotide variants (SNVs), indels (insertions and deletions), rearrangements (fusions), and copy number variations (CNVs). Moreover, limitations in sampling or probe design may constrain the detection of certain variation types, such as CNVs. (9) In the cases when accuracy of an NGS test may be affected, a reliable single-gene testing approach should be considered to validate the NGS result.
Sample preparation
A crucial step in the NGS test is the library construction with DNA or cDNA that is reverse-transcribed from RNA. Although fresh tissue specimens are generally preferred for clinical NGS testing, formalin-fixed paraffin-embedded (FFPE) specimens, tumor cytology specimens, and plasma (cell-free DNA/RNA) also can be used in NGS tests 44, 45 . NGS tests are performed on clinical specimens collected at critical time points during disease management. A multidisciplinary discussion should be undertaken and fully informed consent should be received to allow the use of NGS tests at multiple time points during treatment 44 . The following methods are used for sample collection: (i) Fresh frozen tissues from surgery and biopsy: Snapping frozen tissue in liquid nitrogen is an ideal preservation method for fresh tissues. Otherwise the fresh tissues can be stored in liquid nitrogen or in a -80 °C freezer within 30 minutes after removal from the body to prevent the degradation of nucleic acids such as RNA. Alternatively, fresh tissues can also be stored in preservative reagents and transferred to a -80 °C freezer as soon as possible. The tumor content can be determined by frozen section staining 46 ; (ii) FFPE tissues: Handling of tissues should be performed according to standard pathological operating procedures. Tissues should be fixed in 10% neutral formalin solution within 30 minutes after excision, avoiding the usage of fixatives containing acidic or heavy metal ions. Large specimens should be trimmed to proper sizes and fixed for 6 to 48 hours, but not longer than 72 hours. Biopsy specimens should be fixed for 6 to 12 hours, and the tumor content should be determined by H&E staining before NGS testing [47] [48] [49] ; (iii) Cytology samples: the presence of tumor cells in pleural effusion and ascites samples must be confirmed before NGS testing. Samples meeting quality requirements by cytopathological examination can undergo nucleic acid extraction directly, or FFPE preparation for future use 50, 51 ; (iv) Plasma or blood: cell-free/circulating tumor DNA (cf/ctDNA) is often found in plasma, and the proportion of tumor-derived DNA varies dramatically among distinct types and stages of cancers. Evidence indicates that ctDNA assays provide more reliable results at the time of disease progression. However, there is no evidence of clinical utility to suggest that ctDNA assays are useful for diagnosis of early-stage cancer or screening 52 . EDTA anticoagulation vacuum collection tubes can be used in blood sampling for cfDNA preparation. Plasma should be isolated within 2 hours after about 8-10 mL of whole blood is collected and transported under refrigerated condition, after which cfDNA is extracted. cfDNA should be stored either at -80 °C to avoid repeated freeze-thaw cycles or in the commercial cfDNA collection tubes, which can preserve cfDNA for 3 to 7 days at room temperature if peripheral blood samples need to be transported for a long time. The large amount of genomic DNA (gDNA) released from blood cell diminishes the relative frequency of ctDNA dramatically. Therefore, blood samples with obvious hemolytic signs are not suitable for ctDNA NGS testing. cfDNA samples with suspected gDNA contamination should be first determined by the size distribution analysis of nucleic acid fragments before NGS testing 45 .
The evaluation of sample quality has a profound impact on the interpretation of results. Therefore, it is essential to keep a careful record of sample collection circumstances, transportation details, processing before analysis, and pathological assessment. The evaluation for sample integrity should include the tumor content, number of tumor cells, and processing and transportation carried out according to SOPs. Evaluation methods include visual inspection, microscopic observation, and nucleic acid concentration analysis of plasma samples. If tumor-cell-enriched regions are marked for nucleic acid extraction, then microdissection could be carried out whenever required 45, 46 . (10) Prevention of contamination in sample collection and processing:
Recommendations
(a) The use of disposable materials for sample collection is recommended.
(b) Any residual samples left on instruments from the previous operations must be cleared away, and single-use blades must be changed between samples from different patients 45 . (11) Sample transportation and storage (a) The lab that performs this testing must establish detailed sample shipping SOPs, provide a sample collection manual for clinicians, and require from the logistics personnel to complete relevant records to ensure a safe and trackable shipment. FFPE samples can be transported at room temperature, plasma samples on dry ice, and nucleic acid samples should be transported at 4 °C or under freezing conditions 45 .
(b) Because the clinical sample quality is crucial to the accuracy of clinical NGS tests for tumor driver genes, we recommend that the collection and processing of all types of biological samples should have SOPs.
(c) Each sample undergoing NGS testing should have a unique identifier, including different tissue lesions, sections, and nucleic acid samples from the same patient.
(d) Except for DNA/RNA from plasma or blood samples, specimens involved in morphology should be assessed for tumor content under the microscope, and the proportion of morphologically malignant cells should be recorded.
(e) In general, tissue samples with tumor contents >20% are suitable for NGS testing; if the patient is still willing to have NGS testing performed after being informed, microdissection techniques should be applied to enrich tumor cells as much as possible, or NGS sequencing data volume should be increased to improve sequencing depth. In this situation, sample limitations should be mentioned in the report. More than 50-ng DNA obtained from tissue samples or cfDNA obtained from at least 8-mL whole blood samples are ideal quantities for NGS testing.
(f) QC such as nucleic acid concentration and purity analysis on tissue DNA and plasma cfDNA should be performed before NGS testing.
(g) Tissue DNA should be analyzed for nucleic acid integrity to determine its quality.
(h) Plasma cfDNA should be analyzed for the distribution of fragment lengths to exclude the presence of blood gDNA contamination.
(i) QC for concentration and fragment distribution of the library should be performed after library construction.
(j) The testing laboratory should consider storing additional biological samples for result validation by other technical methods. They may also consider reserving several more slices for subsequent validations by other methods such as IHC, FISH, and PCR when collecting FFPE sections.
NGS workflow
NGS testing is at present mainly used for driver gene sequencing in clinical cancer practice, which represents an important aspect of precise diagnosis and treatment of tumors. The advantages of NGS technology include its highthroughput workflow, mutation frequency analysis, and relative low cost. The disadvantages include lack of bioinformatics analysis software to meet the clinical application, the interpretation of genotypes depending on the accuracy of bioinformatics results, and the challenge of achieving the sequencing depth due to high overall cost 5, [53] [54] [55] [56] . In terms of the application of NGS technology in cancer diagnosis and disease monitoring, laboratories should pay attention to reagent management, sample QA/QC, testing environment, personnel qualification and proficiency, and NGS standards for technical parameters (including library construction, sequencing process, and QC). SOPs should be applied to every NGS test to ensure robust and accurate NGS testing for specific tumors. All aspects of sequencing technology should have standard laboratory records to establish a structured database for management, which can track platform environmental parameters, reagent usage and performance, sample tracking, and quality control data. Laboratories must ensure the accuracy of testing by daily and periodic QC procedures 5 .
In order to meet the highest quality of clinical needs, the testing laboratory must provide a reasonable backup solution to each step of the workflow that is found to be abnormal or inadequate. Backup solutions could involve adopting another molecular diagnostic platform to detect important sites, validating positive results using other technologies, repeating the high-throughput sequencing process, or requesting new specimens, if this is a possibility. 
Recommendations

(21) NGS analysis tools must be validated by an adequate amount of raw data with different variation types and variants allele frequency (VAF) used to establish accuracy and stability of the complete analysis pipeline. (22) The reliability of the analysis pipeline needs validation when more testing genes are included, and the process should include the details of software development and operation records. CSCO CAGC will also organize projects based on proficient validation of software analysis. (23) The testing laboratories must use structured databases to manage diverse kinds of variants including SNPs, indels, rearrangements (fusions), and CNVs with the data storage adopting common formats such as FASTQ, BAM, and VCF for data exchange and external evaluation.
(24) Complete logs should be recorded and saved for distinguishing pipeline version information, tracing sources of abnormal results, and analyzing reproducibility of raw data generated for diagnostic reports. Diagnostic laboratories should keep such databases for at least 15 years. (25) The quality inspection of NGS raw data should be guided by strict operating procedures, with all parameters compared with those of the testing performance evaluation process. The acceptance and rejection criteria should be determined and executed ( Table 1) .
(26) The data analysis process should include pre-analysis, adaptor removal, primer removal, low-quality sequence removal, mapping to a reference genome (alignment), duplicate removal, indel realignment, base quality score recalibration, variant calling, annotation, filtering, and output steps ( Table 2 ). The CAGC-POI project requires a common procedure across different kind of tumors. Genetic variants can be germline or somatic. Somatic events, such as acquired mutations are the most commonly reported variants in cancer genomic studies. However, there is evidence that shows the role of inherited genetic variations in cancer risk, pharmacogenomics, and gene regulation 64 . The interpretation of variations in germline sequences is based mainly on the pathogenicity of a variant for a specific disease, while the interpretation of somatic variants is based on their clinical care effect 65 .
According to the joint consensus issued by the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists, clinical judgment should be used in the absence of normal paired sequencing data to differentiate somatic and germline variants, since many germline pathogenic variants such as TP53, PTEN, and BRCA1/2 also occur as acquired somatic variants. Hence, sequencing of non-tumor tissue should be performed for a definite germline status 65 . In the routine practice of NGS to gene panels without control non-tumor tissue or blood genomic DNA, an alternative method using public SNP databases and/or laboratory baseline cohort SNP data for filtering the germline variants is recommended.
We recommend a clear discrimination between the somatic and germline variants, with somatic variants being more clinically significant in tumor diagnosis and treatment. The biological significance of specific germline variants should be annotated, e.g., BRCA1/2 in breast cancer. Clinically related variants in each tumor type should be highlighted with detailed annotations in test reports. For instance, EGFR mutations on exons 18 to 21, ALK rearrangement, ROS rearrangement, MET exon 14 skipping, HER2 (ERBB2) insertion, and copy number amplification in lung cancer.
Recent studies regarding molecular heterogeneity of tumors have shown that tumor subclones may contain different molecular variants. The presence of heterogeneous subclones affects the overall evolution of the tumor and its response and resistance to targeted therapies. In order to understand the relationship between heterogeneity and clinical outcomes in the metastasis stages, the sequencing depth of NGS should be deep enough for both clinical tumor diagnosis and monitoring of drug resistance 66, 67 . CAGC recommends that the "effective depth" of an NGS testing should be ≥ 500× for tumor samples, and ≥ 2,000× for plasma cfDNA. The data management of CAGC projects should be standardized in terms of standard processes. The consensus will be verified in the following analyses of 100 samples for each tumor type.
NGS reporting and consulting
Due to the complexity of NGS to generate large volumes of information, the test report should be represented according to the following rules: a concise front page with the essential Genetic variant databases with valid scientific evidence should be used for variant classification, and these databases must meet the requirement of good quality or latest guidance. 70 This will facilitate future research in pinpointing their clinical value. 65 Due to the development of many NGS studies, FDA has approved several NGS-based multigene diagnostic services, including Oncomine Dx from Thermo Fisher, Integrated Mutation Profiling of Actionable Cancer Targets (IMPACT) from Memorial Sloan Kettering (MSK), and Foundation One CDx from (FMI). 71 FMI reports not only the SNP, indel, rearrangement and copy number alterations (CNA) but also microsatellite instability (MSI) and TMB. Further studies and validations are needed to apply these biomarkers to the Chinese population.
It is recommended to integrate NGS data from different types of tumors into the same database, which will be helpful for the referencing of variation information in different tumor types for clinical applications. Therefore, we recommend the format and content of the report to be standardized, while providing enough flexibility to adapt to the development trend in the short term (updates regarding actionable genes and testing content). Appendix 1 is an example of a clinical tumor NGS test report. The report should include patient ID, disease information, sample information, testing methodology information, main results, interpretation of results, and the signature of the operator and the lab expert (molecular oncologist or genetics specialist). The reportable range should be based on NGS testing purposes and qualified detection regions. For example, it is not necessary to report all the genomic alterations by whole-exome sequencing (WES) for lung cancer. However, it is necessary to inform clinicians that there may be potential "non-attended region" variations. The NGS test report should be concise, clear, and understandable, and it should provide the complete necessary information for the clinician to make decisions about the current clinical target-therapy strategy. The interpretation of results must be objective and unbiased, and the genomic variants associated with the tumor should be clearly described. The report should not only describe the curative or predictive correlations from previous studies regarding disease correlation, but also suggest the no-treatment recommendation. Only clinicians or the multidisciplinary team (MDT) can make clinical decisions based on the NGS testing results. Multidisciplinary team discussions are required for genetic counseling, and multiparty communication among the experts in laboratory, cancer genetics, molecular biology, bioinformatics, and pathology is essential for the final clinical decision.
Informed consent
Informed consent form must contain: (1) The basis for testing, including medical guidelines, expert consensus, treatment norms and other content, to inform patients of the significance and purpose of the testing; (2) The conception that the testing process may have limitations, such as the sample volume sufficient for DNA/RNA extraction and failure of test due to bad sample quality. If such a situation occurs to the patient, the patient and family members should be informed as soon as possible, and next steps should be discussed; (3) Gene sequencing can assist in personalized therapy; however, the final decision must be made by the clinician; (4) Testing results only refer to the corresponding samples submitted; (5) The patient's ID, clinical information, and test results must be kept confidential by the testing institution. Patients must be aware of the above agreement terms and sign informed consent forms before testing 20, [72] [73] [74] . (27) NGS tests should be carried out after informed consent, genetic counseling, and explanation of the purpose, advantages, and disadvantages of NGS tests under disease conditions to patients. (28) Clinicians and patients need to be informed of the limitations of the test, including driver gene information, reportable range, and the analytical sensitivity and specificity.
Recommendations
Differences between research and diagnostic NGS tests
Because of the rapid technology development and improvement of experimental abilities, the boundaries between research NGS and diagnostic NGS have been blurred. However, it should be made explicit whether a specific NGS test is used for research or diagnosis in practical applications. The purpose of diagnostic NGS is to answer the question of whether a patient's DNA contains a specific genetic variation in the tumor (actionable variation). Normally, only a certified laboratory is qualified to perform diagnostic NGS tests. For hypothesis-driven research purposes, research NGS tests only provide limited or uncertain clinical significance for enrolled patients. The massive quantities of data obtained from WES or WGS not only serve for tumor diagnosis, but also generate new research hypotheses 20 . (29) Clinically relevant information from research NGS test can be recorded in a patient's medical records only after the results are validated under a clinical diagnosis condition. (30) Both research and diagnostic NGS test results should be used to establish database management to facilitate the comparison with local, regional, national, or international databases, which will be helpful for clinical classification of variants.
Recommendations
CAGC-POI project NGS test supervision and management
To ensure the same quality and continuity, the CSCO CAGC expert group shall supervise all NGS projects in CAGC-POI clinical practice, clinical trial, and research.
This will entail on-site inspections, document management, process monitoring, and external evaluation of testing samples to ensure that every NGS laboratory executing the CAGC-POI projects is at the highest quality standards.
